1. Home
  2. VIRT vs EWTX Comparison

VIRT vs EWTX Comparison

Compare VIRT & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtu Financial Inc.

VIRT

Virtu Financial Inc.

HOLD

Current Price

$35.46

Market Cap

2.8B

Sector

Finance

ML Signal

HOLD

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

HOLD

Current Price

$23.70

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VIRT
EWTX
Founded
2008
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.5B
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
VIRT
EWTX
Price
$35.46
$23.70
Analyst Decision
Hold
Buy
Analyst Count
7
10
Target Price
$41.43
$37.30
AVG Volume (30 Days)
731.5K
1.3M
Earning Date
10-29-2025
11-06-2025
Dividend Yield
2.71%
N/A
EPS Growth
132.69
N/A
EPS
4.62
N/A
Revenue
$2,694,104,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$7.68
N/A
Revenue Growth
41.05
N/A
52 Week Low
$31.89
$10.60
52 Week High
$45.77
$35.50

Technical Indicators

Market Signals
Indicator
VIRT
EWTX
Relative Strength Index (RSI) 55.38 62.19
Support Level $34.16 $22.51
Resistance Level $35.89 $26.30
Average True Range (ATR) 0.86 1.46
MACD 0.07 -0.10
Stochastic Oscillator 77.99 60.25

Price Performance

Historical Comparison
VIRT
EWTX

About VIRT Virtu Financial Inc.

Virtu Financial Inc is a financial firm that leverages technology to deliver liquidity to the world-wide markets and transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Share on Social Networks: